Pages that link to "Q46051563"
Jump to navigation
Jump to search
The following pages link to Ryanodine receptor type 1 gene mutations found in the Canadian malignant hyperthermia population (Q46051563):
Displaying 13 items.
- Genetic risk for malignant hyperthermia in non-anesthesia-induced myopathies (Q35209452) (← links)
- Novel excitation-contraction uncoupled RYR1 mutations in patients with central core disease (Q36586052) (← links)
- Ryanodine receptor type 1 gene variants in the malignant hyperthermia-susceptible population of the United States (Q36786555) (← links)
- RYR1 mutations as a cause of ophthalmoplegia, facial weakness, and malignant hyperthermia (Q37397231) (← links)
- Functional and genetic characterization of clinical malignant hyperthermia crises: a multi-centre study (Q37497206) (← links)
- Analysis of histomorphology in malignant hyperthermia-susceptible patients (Q44350160) (← links)
- Malignant Hyperthermia in the Post-Genomics Era: New Perspectives on an Old Concept (Q47253099) (← links)
- Ecstacy-induced delayed rhabdomyolysis and neuroleptic malignant syndrome in a patient with a novel variant in the ryanodine receptor type 1 gene (Q48151960) (← links)
- Phenotype and genotype of muscle ryanodine receptor rhabdomyolysis-myalgia syndrome. (Q54116685) (← links)
- Clinical and genetic findings in a large cohort of patients with ryanodine receptor 1 gene-associated myopathies (Q57334263) (← links)
- Genetic epidemiology of malignant hyperthermia in the UK (Q59882254) (← links)
- Bayesian modeling to predict malignant hyperthermia susceptibility and pathogenicity of RYR1, CACNA1S and STAC3 variants (Q90324643) (← links)
- Abnormal calcium signalling and the caffeine-halothane contracture test (Q90717797) (← links)